Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMP-023
- Development stage
- Preclinical
- Lead developer
- Amphastar France Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
AMP-023 is a generic metered-dose inhaler (MDI) candidate being developed by Amphastar France Pharmaceuticals, a subsidiary of Amphastar Pharmaceuticals. Currently in the preclinical stage, AMP-023 is part of Amphastar's pipeline of complex generic products. It is designed for administration via the inhalation route to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). As a generic MDI, it is intended to be a bioequivalent version of an existing branded inhalation therapy, although the specific reference listed drug (RLD) and active ingredient have not been publicly confirmed in the provided pipeline context.
Beyond the preview
Go deeper on AMP-023.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMP-023.